Ocular Melanoma clinical trials at UCSF
1 research study open to eligible people
Ocular melanoma is a rare cancer that occurs in the eye. UCSF is conducting research on a combination therapy using Darovasertib and Crizotinib for those with advanced uveal melanoma. The trials are designed to explore effective treatments for this challenging disease.
Showing trials for
IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
open to eligible people ages 18 years and up
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
San Francisco, California and other locations
Last updated: